COMMUNIQUÉS West-GlobeNewswire

Corbus Pharmaceuticals Announces Proposed Public Offering
31/01/2024
NORWOOD, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced that it [...]
Guardion Health Sciences Announces Entry into Definitive Agreement to Sell its Well-Known Viactiv® Brand and Business to Doctor’s Best Inc.
31/01/2024
HOUSTON, TEXAS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) announced today that it has signed an equity purchase agreement to sell its Activ Nutritional [...]
Trinity Biotech plc to Host Investor Call
30/01/2024
Conference Call Scheduled for Wednesday, January 31, 2024 at 8:30 AM ET DUBLIN, Ireland, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of [...]
Investors and Innovators Representing more than $309B in Biotech Assets and 624 New Drugs in Development Urge the Congressional Budget Office to Update its Drug R&D Policy Impact Model
30/01/2024
Letter responds to CBO’s call for input on how investors make decisions about funding research of new drugs WASHINGTON, Jan. 30, 2024 (GLOBE NEWSWIRE) -- More than 350 biotech investors, executives, and economists today [...]
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
30/01/2024
SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and [...]
STERIS Announces Dividend of $0.52 per share
30/01/2024
DUBLIN, IRELAND , Jan. 30, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.52 per share. The dividend is [...]
Amniowrap2™ Product Launch Leads Year of Highlights for BioStem Technologies
30/01/2024
BioStem provides a business update and highlights recent accomplishments Preliminary fourth quarter net revenues of $11.5 million and full year 2023 net revenues of $16.7 million National Pricing for Amniowrap2™ [...]
Stryker reports 2023 operating results and 2024 outlook
30/01/2024
Portage, Michigan, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2023: Fourth Quarter Results Reported net sales increased 11.8% to $5.8 billion [...]
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
30/01/2024
JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today [...]
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
30/01/2024
BASEL, Switzerland and LONDON and NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, February 13, 2024, to [...]
Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
30/01/2024
CARLSBAD, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science [...]
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
30/01/2024
SAN CARLOS, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial [...]
Autonomix Medical, Inc. Completes $8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use – Over 100 patents in portfolio
30/01/2024
Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix’s development and strategic opportunities THE WOODLANDS, TX, Jan. 30, 2024 (GLOBE [...]
EverythingALS Releases First Open Data From the Austen Speech Study
30/01/2024
Data from the citizen-driven initiative is made public for the first time SEATTLE, Jan. 30, 2024 (GLOBE NEWSWIRE) -- EverythingALS, a non-profit organization focused on research and technology, is pleased to announce [...]
Eurobio Scientific: FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP
30/01/2024
FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP Continued total year growth in core business revenues, up 39% Successful deployment of the Group's strategy: Proprietary products up at 30% of revenues [...]
Eurobio Scientific : EXERCICE 2023, CONFIRMATION DE LA TRANSFORMATION STRATEGIQUE
30/01/2024
EXERCICE 2023, CONFIRMATION DE LA TRANSFORMATION STRATEGIQUE Progression du chiffre d’affaires annuel cœur d’activité à +39% Succès du déploiement de la stratégie du Groupe : Produits propriétaires : 30% du Chiffre d’ [...]
Defender Pharmaceuticals Receives Complete Response Letter from the U.S. Food and Drug Administration for its Intranasal Scopolamine (DPI-386) New Drug Application for the Prevention of Nausea and Vomiting Induced by Motion in Adults
30/01/2024
ST. LOUIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Defender Pharmaceuticals, Inc. (the “Company” or “Defender”), a privately held life sciences company based in St. Louis, today announced that the U.S. Food and Drug [...]
Novo Nordisk A/S - share repurchase programme
30/01/2024
Bagsværd, Denmark, 30 January 2024 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 [...]
Kairos Pharma Doses First Patient in Phase 2 Trial of Lead Drug Candidate ENV105 with Apalutamide to Improve Therapy Sensitivity for Castrate-Resistant Prostate Cancer
30/01/2024
LOS ANGELES, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd., a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune suppression, announces [...]

Pages